Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

University Hospital, Clermont-Ferrand30 enrolled

Overview

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

The only visit to the study will be carried out during a usual dialysis session in the intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Study Type

OBSERVATIONAL

Enrollment

Conditions

End Stage Renal Disease

Interventions

blood samplingOTHER

2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major patient; * Man or woman ; * Treated with intermittent hemodialysis for chronic renal failure; * In whom intermittent hemodialysis with citrate solution for regional anticoagulation is indicated; * Affiliated with a social security scheme; * Having given a signed agreement after detailed explanation of the protocol on the basis of the information sheet and likely to comply with it Exclusion Criteria: * Severe hepato-cellular insufficiency (PT \<50%, INR\> 1.5 without anticoagulant); * Hemoglobin level \<7 g / dL * Presenting a psychiatric pathology or cognitive impairment rendering him unable to give informed consent; * Persons under guardianship, curatorship, deprived of liberty or safeguard of justice * Pregnant or breastfeeding women * Patient's refusal to participate in the study.

Locations (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Ionized calcium level

measured at dialyzer inlet, in mmol/L

Time frame: day 0

Total calcium level

measured at dialyzer inlet, in mmol/L

Time frame: day 0

Total citratemia

measured at dialyzer inlet, in mmol/L

Time frame: day 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.